DRKS00000605已完成不适用
Open label, prospective observational, multi-center trial in postmenopausal, hormone receptor positive breast cancer patients treated with eithertamoxifen or an aromatase inhibitor. Examination of the predictive value of biological markers AEBS/mEH, active tamoxifen metabolites and TGF beta system for response and non response of tamoxifen treatment. - IKP 211
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,285
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Female
入选标准
- •Histopathologic confirmed diagnosis of breast cancer, stage TxNxM0, postmenopausal status, hormone responsive status (positive estrogen and/or progesteron receptors), clinically indicated completion of adequate surgery and chemotherapy, radiotherapy may be planned, planned adjuvant tamoxifen or aromatase inhibitor treatment for five years or planned switch of endocrine therapy provided Tamoxifen is given for at least 2 years, age > 18 years, performance status: ECOG < 2, written informed consent
排除标准
- •Negative hormone receptor status, medical history of prior tamoxifen or aromatase inhibitor treatment, concurrent hormone substitution, suspected or confirmed poor compliance, other co-existing malignancies or malignancies diagnosed within the last 5 years, in the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable respiratory, cardiac, hepatic or renal disease) significantly compromising life expectancy.
研究者
相似试验
已完成
4 期
A Clinical Trial to study the Safety And Efficacy of ACIDEEM Plus Tablet Vs Pantoprazole 40mg tablet for Reflux Disease, Regurgitation and Heartburn, Acidity in Indian adults for decreasing upper Gastrointestinal symptoms.CTRI/2023/03/050245Healing Hands & Herbs Pvt Ltd
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)EUCTR2015-003653-17-CZBiotest AG34
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)Chronic primary immune thrombocytopenia (ITP)MedDRA version: 19.0 Level: LLT Classification code 10051057 Term: Idiopathic thrombocytopenia System Organ Class: 100000004851EUCTR2015-003653-17-DEBiotest AG40
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)Chronic primary immune thrombocytopenia (ITP)MedDRA version: 19.0 Level: LLT Classification code 10051057 Term: Idiopathic thrombocytopenia System Organ Class: 100000004851EUCTR2015-003653-17-ESBiotest AG40
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)EUCTR2015-003653-17-HUBiotest AG40